Eagle Pharmaceuticals Inc. (EGRX)

Business: Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

IPO Date: 12-Feb-2014

Founder, Pres, CEO & Director: Mr. Scott L. Tarriff

Chief Financial Officer: Mr. Brian Joseph Cahill

Listing: NASDAQ: EGRX

Country: United States

Headquarters: Woodcliff Lake, NJ

Website: https://www.eagleus.com

Market cap: $466.45 Mln

Revenue (TTM): $246.17 Mln

Earnings (TTM): $35.85 Mln

Cash: $69.52 Mln

Total Debt: $27.63 Mln

Insider's Holding: 12.54%

Liquidity: Low

52 Week range: $33.72 - 58.25

Shares outstanding: 13,214,600

10 Years Aggregate:

• CFO: $253.22 Mln
• EBITDA: $188.74 Mln
• Net Profit: $150.29 Mln